Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023 16:06 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
June 14, 2023 07:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis
June 07, 2023 07:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
May 31, 2023 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
May 11, 2023 16:01 ET
|
Ventyx Biosciences, Inc.
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of...
Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023
May 04, 2023 16:05 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 24, 2023 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
March 23, 2023 16:01 ET
|
Ventyx Biosciences, Inc.
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial...
Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
March 15, 2023 16:05 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure
March 11, 2023 13:21 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank (“SVB”) has been closed by the California Department of...